comparemela.com


Recombinant Two-Component COVID-19 Vaccine (ReCOV) was approved for International Phase II/III Clinical Trial ReCOV induced high levels of neutralizing antibodies against SARS-CoV-2 and Variants of Concern such as Omicron and Delta Rhecogen , a subsidiary focused on mRNA vaccines of the infectious diseases, launched the world's first lyophilized mRNA vaccine TAIZHOU, China, Jan. 17, 2022 /PRNewswire/ -- The...

Related Keywords

China ,Taizhou ,Jiangsu ,Philippines ,New Zealand ,Liu Yong ,Fengcai Zhu ,Jiangsu Medical Products Administration ,Taizhou Medical New Industrial Development Zone ,Jiangsu Recbio Technology Co Ltd ,Human Health ,International Phase ,Jiangsu Provincial Center ,Recombinant Two Component ,General Manager ,Pharmaceutical Production License ,Good Manufacturing Practices ,Disease Control ,Taizhou Medical New ,High Tech Industrial Development Zone ,Professor Fengcai Zhu ,Innovative Vaccine ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.